Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28790390 | 0.93 | CYP17A1 (0.44) | IDO1TDO2ACHEAOC3DAO | |
| SCHEMBL1415320 | 0.85 | ESR1 (0.38) | HTTTRPA1SLC6A2SLC6A3 | |
| SCHEMBL1046731 | 0.78 | IDO1 (0.42) | IDO1TDO2ACHEAOC3DAO | |
| SCHEMBL2732165 | 0.77 | IDO1 (0.46) | IDO1TDO2ACHEAOC3HDAC3 | |
| SCHEMBL7893366 | 0.77 | ESR1 (0.52) | IDO1TDO2ACHEAOC3DAO | |
| SCHEMBL12027408 | 0.77 | IDO1 (0.46) | IDO1TDO2ACHEAOC3DAO | |
| SCHEMBL9510147 | 0.77 | PTGS2 (0.39) | CYP17A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4427290 | 0.77 | IDO1 (0.46) | IDO1TDO2ACHEAOC3HDAC3 | |
| SCHEMBL84956 | 0.77 | IDO1 (0.46) | IDO1TDO2ACHEAOC3DAO | |
| SCHEMBL5695686 | 0.77 | TYR (0.46) | IDO1HTTTRPA1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 532 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102408413-A | Anticoccidial compound and preparation method and application thereof | CHINA ANIMAL HUSBANDRY INDUSTRY CO LTD | 2012-04-11 | — | — | CN | claimed |
| CN-102311425-A | Anticoccidiosis compound and preparation method as well as application thereof | CHINA ANIMAL HUSBANDRY INDUSTRY CO LTD | 2012-01-11 | — | — | CN | claimed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| US-5132049-A | Containing an ether function and at least partially fluorinated radical | SOLVAY & CIE (SOCIETE ANONYME) (BE) | 1992-07-21 | — | — | US | disclosed |
| WO-1991018602-A1 | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| US-5026729-A | Lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1991-06-25 | — | — | US | disclosed |
| CN-1049347-A | Novel 1-oxa--2-oxo-8-azaspiro [4,5] decane derivative, the method that contains the pharmaceutical composition of this analog derivative and prepare them | RICHTER GEDEON VEGYESZET (HU) | 1991-02-20 | — | — | CN | disclosed |
| WO-1990002740-A1 | 2-OXA-BICYCLO[2.2.1]HEPTANE DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1990-03-22 | — | — | WO | disclosed |
| CN-1007248-B | PROCESS FOR MANUFACTURING OF FLOOD SUGAR REDUCING MEDICINE-THIAZOLIDINEDIONS | PFIZER (US) | 1990-03-21 | — | — | CN | disclosed |
| EP-0320983-A2 | Piperidinyl compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-06-21 | — | — | EP | disclosed |
| CN-86104075-A | Preparation method of hypoglycemic agent-thiazolidinedione | — | 1987-03-11 | — | — | CN | disclosed |
| EP-0159915-A2 | Process for making ring-halogenated styrenes and their use | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1985-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | IDO1 2038/4885TDO2 4243/4885ACHE 3561/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | IDO1 540/4885TDO2 2346/4885ACHE 4667/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | IDO1 259/4885TDO2 3173/4885ACHE 3965/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | IDO1 435/4885TDO2 3264/4885ACHE 1309/4885 |
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | IDO1 2010/4885TDO2 2352/4885ACHE 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.